FDA Approves Seno Medical’s Ground-Breaking Breast Cancer Diagnostic Technology
San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions.
- San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions.
- The companys Imagio Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may - or may not - require more invasive diagnostic evaluation.
- The companys OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
- Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.